T2 Biosystems has raised $23 million through series D venture capital financing. The investment round was led by new investor Aisling Capital, while existing investors, including Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners and WS Investments, also participated.

Josh Bilenker, managing director, principal at Aisling Capital, will join T2 Biosystems’ board of directors. The company intends to use the proceeds to support ongoing development and clinical trials and commercialization of their T2MR diagnostic technology.

Click here for the release from T2 Biosystems.